Sensus Healthcare: HC Wainwright & Co. reiterates the 'Buy' Rating, The Target Price is $12

HC Wainwright & Co. reiterates 'Buy' rating on Sensus Healthcare(SRTS).

The target price is unchanged and still at 12 .

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-04-04	HC Wainwright & Co.	Reiterates	Buy	Buy	$12	$12
2025-03-11	Lake Street	Maintains	Buy	Buy	$13	$18

[Recent Earning Results] Sensus Healthcare posted the Q4 of its 2024 financial results on 3/5/2025, reporting total revenue of USD 41.81 million for the year, up 71.31% from USD 24.41 million year over year, reporting net income of USD 6.65 million for the year, up 1270.52% from USD 0.49 million year over year.

[Company Profile] Sensus Healthcare, Inc., a Delaware limited liability company, was formed on May 7, 2010. The company is a medical device company committed to providing highly effective, non-invasive, and cost-effective treatments for both oncological and non-oncological skin conditions. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is based on over a decade of dedicated research and development, and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in hundreds of thousands of patients around the world.